Search articles in Company Focus

Found 88 articles

  • About RSSL

    About RSSL

    • 28 Feb 2024

    RSSL is a cutting-edge contract research organisation, pushing the boundaries of science and innovation to help make our world safer, healthier and more sustainable

  • About Curia

    About Curia

    • 28 Feb 2024
    • Editor

    Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with biopharmaceutical customers to bring life-changing therapies to market. Our biologics and small molecule offerings span discovery through commercialization, with integrated regulatory and analytical capabilities.

  • About TrakCel

    About TrakCel

    • 28 Feb 2024
    • PharmiWeb Editor

    TrakCel is the market leading developer of integrated cell orchestration solutions and services.

  • About Curve Therapeutics

    About Curve Therapeutics

    • 27 Feb 2024
    • PharmiWeb Editor

    Curve Therapeutics is a private biotechnology company pioneering a revolutionary intracellular screening platform to enable the discovery of innovative therapeutics that address complex and challenging disease targets with the potential to transform the lives of patients

  • About PACE

    About PACE

    • 22 Feb 2024
    • Editor

    PACE is a new approach to tackling one of the world’s most complex health challenges – antimicrobial resistance (AMR). PACE’s ambition is to work with the AMR community to help progress early-stage antimicrobial drug and diagnostic projects with greater speed, support and confidence – giving the best AMR innovations the greatest chance of success.

  • About Kling Biotherapeutics

    About Kling Biotherapeutics

    • 22 Feb 2024
    • PharmiWeb Editor

    Kling Biotherapeutics boasts a fully owned IP portfolio featuring innovative platform technologies Kling-Select and Kling-Evolve. These cutting-edge technologies enable simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells.

  • About Mainz Biomed

    About Mainz Biomed

    • 21 Feb 2024
    • Editor

    The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

  • About Terumo Blood and Cell Technologies

    About Terumo Blood and Cell Technologies

    • 20 Feb 2024
    • Editor

    Terumo Blood and Cell Technologies (Terumo BCT) is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions.

  • About IGC Pharma

    About IGC Pharma

    • 19 Feb 2024
    • Editor

    IGC Pharma is pursuing innovative solutions to fight Alzheimer’s disease and related challenges. IGC Pharma’s portfolio comprises five assets, all with a singular mission – to transform the landscape of Alzheimer’s treatment.

  •  About Sartorius Stedim Biotech

    About Sartorius Stedim Biotech

    • 16 Feb 2024
    • Editor

    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically.

  • About Medigene AG

    About Medigene AG

    • 15 Feb 2024
    • Editor

    Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors.

  • About NextPoint Therapeutics

    About NextPoint Therapeutics

    • 14 Feb 2024
    • Editor

    NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 axis, also known as B7-H7.

  • About Zymeworks Inc.

    About Zymeworks Inc.

    • 13 Feb 2024
    • Editor

    Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics.

  • About Zetta Genomics

    About Zetta Genomics

    • 9 Feb 2024
    • Editor

    Founded in 2019, Zetta Genomics is a fast-scaling genomic data technology company headquartered in Cambridge, UK, with offices in Valencia, Spain. A spin-out from the University of Cambridge and Genomics England, Zetta Genomics concentrates genomic, big data and start-up expertise to deliver data management fit for the precision medicine era.

  • About  Karuna Therapeutics

    About Karuna Therapeutics

    • 8 Feb 2024

    Karuna Theraputics are a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. We pride ourselves on our deep expertise in neuroscience and inventive thinking around drug discovery and development. Since our inception, we have worked relentlessly to advance a pipeline of novel medicines with the goal of making a profound difference in the lives of those affected by these complex conditions.

  • About Roquefort Therapeutics

    About Roquefort Therapeutics

    • 8 Feb 2024
    • Editor

    Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

  • About Almeda Pharmaceuticals AG

    About Almeda Pharmaceuticals AG

    • 8 Feb 2024
    • PharmiWeb Editor

    Almeda Pharmaceuticals AG is a pharmaceutical company located in Zug, Switzerland. Our mission is to be sustainable in providing value-added, high quality pharmaceutical products to patients.

  • About Chiesi Group

    About Chiesi Group

    • 8 Feb 2024
    • PharmiWeb Editor

    Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care.

  • About Invizius

    About Invizius

    • 7 Feb 2024
    • Editor

    Invizius is developing second generation complement therapies to treat inflammatory, fibrotic and autoimmune disorders. Invizius’ proprietary approach was born out of over ten years of research by Dr Andy Herbert into how pathogenic microbes evade the human complement system.

  • About Galen Pharma

    About Galen Pharma

    • 6 Feb 2024
    • Editor

    Galen is a privately owned pharmaceutical sales and marketing company, headquartered in Craigavon (Northern Ireland) and product presence in 25 locations covering each continent across the globe.